Expiring federal contract
36C24623C0012 — Ino Therapeutics LLC
Department of Veterans Affairs
- Contract / PIID
- 36C24623C0012
- Incumbent
- Ino Therapeutics LLC
- Incumbent UEI
- XXQHL619FUN6
- Current end date
- December 31, 2026
- Potential total value
- $270,238
- Obligated
- $270,238
- NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- PSC
- Q521 — MEDICAL- PULMONARY
- Set-aside
- Full & Open
- Start date
- January 1, 2023
- Place of performance
- NJ
- Award type
- DEFINITIVE CONTRACT
Source: USASpending.gov award record, last checked November 19, 2026. Place of performance as reported by USASpending.
What the contract covers
NITRIC OXIDE GAS
Likely rebid window (estimate)
- Sources Sought / RFI: about Dec 2025 – Jun 2026 (6–12 months before the end date)
- RFP: about Aug 2026 – Oct 2026 (2–4 months before the end date)
In the final months before the current end date.
Estimated from the current end date using typical federal recompete timing. Agencies set their own schedules, and contracts are often extended. This is not a published solicitation date.
Track this recompete free
- Change history: 1 recorded change to the end date, value or incumbent. Sign up to see each one.
- Alerts: get an email when the end date moves or the follow-on is posted.
- Contacts: the buying office and small-business contacts for this agency.
Other contracts expiring at Department of Veterans Affairs (NAICS 325412)
- 36C25927F0028 — Janssen Biotech INC · ends November 20, 2026 · $385K
- 36C24126F0039 — Medi-physics, INC. · ends November 21, 2026 · $100K
- 36C25026N0181 — Schaaf Drugs, LLC · ends November 22, 2026 · $681K
- 36C24626N0323 — Cardinal Health 414, LLC · ends November 30, 2026 · $323K
- 36C25226P0101 — Petnet Solutions, INC. · ends November 30, 2026 · $110K
- 36C26023P0532 — Cardinal Health 414, LLC · ends November 30, 2026 · $337K
- 36C26224P0297 — Rls (USA) INC. · ends November 30, 2026 · $1.1M
- 36C26226N0112 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $4.3M
- 36C26227N0156 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $769K
- 36C24726F0053 — Exelan Pharmaceuticals INC · ends December 7, 2026 · $4.8M